Nvidia is now the most under-owned megacap tech stock
WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (Tevogen Bio Holdings Inc. or Company) (Nasdaq: TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald.
The conference, held on May 13, 2025, at The Liberty Science Center in Jersey City, NJ, historically brings together investors, BD professionals, academic collaborators, innovators and biopharmaceutical industry executives to foster strategic partnerships, drive funding, and accelerate collaboration, with the ultimate goal of advancing medical innovation and transforming the future of healthcare.
I look forward to joining in the upcoming panel discussion hosted by BioNJ, said Dr. Saadi. This is a critical moment for the biotechnology industry to address market volatility and its potential impact on patient outcomes. The topic is closely aligned with Tevogen Bio’s mission to advance accessibility and affordability to lifesaving treatments.
The conference’s action-packed agenda, featuring 1:1 partnering sessions, company pitch presentations, the Industry Connections Desk, exhibits, extensive networking opportunities and engaging plenary discussions, was thoughtfully designed to provide entrepreneurs with a dynamic environment geared toward growth and collaboration, said BioNJ President and CEO Debbie Hart. With that in mind, we’re thrilled to welcome Dr. Saadi and his fellow panelists to share their invaluable insights during Paths to Liquidity: Strategies for Adapting to a Volatile Market. Attendees are certain to walk away with meaningful, actionable takeaways.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Source: Tevogen Bio Inc
TVGN: A Bull or Bear Market Play?
Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if TVGN is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.
Unlock ProPicks AI now